Mipasetamab uzoptirine

尤佐米帕妥单抗

Report date: 2025/05/23 20:00:56

Base Information

Drug NameMipasetamab uzoptirine
Drug Alias NameMipasetamabADCT-601BGB-6011H12-GaINAcN31H12-HAKB
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VA linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > PBD dimer SG3199 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDNA cross linking agentsAXL receptor tyrosine kinase inhibitors
TargetsDNAAXL receptor tyrosine kinase
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomFrance +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAdc Therapeutics Sa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOverland ADCT BioPharmaAdc Therapeutics Sa
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A